Skip to main content

Table 1 Demographic and clinical characteristics of all participants of the study

From: Chemotherapy-induced cognitive impairment in hematological malignancies

  Number Percentage
Diagnosis AML 45 30.00
ALL 15 10.00
CML 16 10.67
CLL 20 13.33
MDS 2 1.33
Lymphoma 25 16.67
MM 27 18.00
Chemotherapy protocol Intensified protocol 56 37.33
TKIs 13 8.67
Velcade 27 18.00
Others 54 36.00
Route of administration chemotherapy Oral 15 10.00
Parenteral 135 90.00
Comorbidities No comorbidities 104 69.33
HTN 16 10.67
DM 10 6.67
Viral hepatic infection 8 5.33
More than one 12 8.00
Remission status Remitted 103 68.67
Resistant or refractory 47 31.33
  1. AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, CML chronic myeloid leukemia, CLL chronic lymphocytic leukemia, MDS myelodysplastic syndrome, MM multiple myeloma, TKIs tyrosine kinase inhibitors, HTN hypertension, DM diabetes mellitus. Intensified protocols include the following: 3 + 7, HIDAC, hyper-CVAD, FCR, ABVD, and R-CHOP. Other chemotherapies include the following: low-dose ara-c, 5-azacitidine, CVP, and chlorambucil-based therapy